CURIES__WIE GEHTS WEITER????? - 500 Beiträge pro Seite

[Wuscher]

moin moin
so nun ist CURIS ja mächtig verprügelt worden
50% minus ist schon ein ganz mächtiger brocken

wars das jetzt mit CURIS??
oder ist CURIS immer noch ein wert
mit guten aussichten???
mfg

[Lima2000]

Also ich bleib mal drin.
Dass die Zulassung von OP1 nicht auf Anhieb geklappt hat,
sollte man nicht überbewerten.Nächstes Prärarat ist Chondrogel.
vielleicht haut das mal rein.
Lima

[austrobull]

Curis Inc. Reiterated `Strong Buy` at Prudential Vector
By Sybil Carlson
Princeton, New Jersey, Jan. 30 (Bloomberg Data) -- Curis Inc. (CRIS US) was reiterated ``strong buy`` by analyst Peter F Drake Phd at Prudential Vector Healthcare Group. The price target is $15.

[austrobull]

Press Release
Protein Families Under Development by Curis Shown to Expand Human Blood Stem Cells
CAMBRIDGE, Mass.--(BW HealthWire)--Jan. 31, 2001--Researchers have demonstrated for the first time the key role of two protein families known as sonic hedgehog and bone morphogenic protein in the expansion of human blood stem cells that retain the capacity to differentiate into any one of the body`s different blood cells. Proprietary technology related to the sonic hedgehog and bone morphogenic proteins is under development by Curis, Inc. (NASDAQ: CRIS - news).
This research finding may permit the development of a universal hematopoietic (blood and immune system) stem cell product that could be used with differentiation factors such as granulocyte colony-stimulating factor (GCSF) and erythropoietin (EPO) to treat a broad variety of disorders, including infections, malignancies and anemia.
Published in Nature Immunology (February 2001), this finding shows that the signaling pathway that causes human blood stem cells to proliferate involves an interplay between sonic hedgehog and a target gene identified as bone morphogenic protein-4.
``The retention of differentiation capabilities, even after the induced expansion of these stem cells, marks an exciting point of departure for new therapies in regenerative medicine and cell replacement therapy,`` said Doros Platika, M.D, president and chief executive officer of Curis. ``The two protein families identified in this study interact to control one of the critical functions of the human body known as hematopoiesis, or the formation of the blood and immune system. Both families are central elements in the Curis intellectual property and technology portfolio. Curis is uniquely positioned, therefore, to develop and commercialize products based on discoveries related to these proteins.``
Dr. Mick Bhatia of The John P. Robarts Research Institute and the University of Western Ontario, is the senior author of the paper. Dr. Bhatia`s team showed that the interaction of sonic hedgehog and bone morphogenic protein-4, in combination with the effect of cytokines (proteins involved in cell communication), causes stem cells to divide, with the resulting cells retaining their unique ability to develop into any one of the body`s different blood cells.
Previously, the application of cytokines to human blood stem cells was shown to cause the cells to differentiate into specialized cells such as red blood cells, used to treat anemia, and white blood cells to treat infections. These specialized cells, however, no longer have the potential to form multiple blood cell types, a critical feature of human blood stem cells.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Registration Statement filed on Form S-1 with the Securities and Exchange Commission on December 19, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.

[Wuscher]

moin moin
soll OP 1 den nachgebessert werden?
oder ist der zug abgefahren?
mfg